

SUMMARY OF FINANCIAL STATEMENTS (Consolidated)
For The Fiscal Year Ended March 31, 2009

Kyowa Hakko Kirin Co., Ltd.

April 28, 2009

Stock Code: 4151

Listed exchanges: Tokyo, 1st section

URL: <http://ir.kyowa-kirin.co.jp/english/index.cfm>

Inquiries: Tetsuro Kuga, General Manager

President Yuzuru Matsuda

Corporate Communications

Department

Scheduled date of General Meeting of Shareholders: June 25, 2009

Telephone: 81-3-3282-0009

Scheduled date of submission of Financial Report: June 25, 2009

Scheduled start date of dividend payment: June 26, 2009

1. Consolidated Financial Results for the Fiscal Year Ended March 31, 2009

(Amounts less than one million yen have been ignored)

1) Consolidated Operating Results

Millions of yen; % changes are from the previous fiscal period

	FY Ended March 31, 2009		FY Ended March 31, 2008	
		Change (%)		Change (%)
Net sales	460,183	17.4	392,119	10.7
Operating income	45,387	15.2	39,390	28.3
Recurring income	46,412	22.2	37,996	23.0
Net income	11,726	(50.0)	23,477	84.9
Net income per share (¥)	¥20.43		¥59.03	
Fully diluted net income per share (¥)	¥20.42		¥58.99	
Return on equity (%)	2.2%		9.5%	
Recurring income to total capital ratio (%)	6.4%		9.8%	
Operating income to sales ratio (%)	9.9%		10.0%	

Income (loss) from equity method investment: FY ended March 31, 2009: ¥1,211 million

FY ended March 31, 2008: ¥1,125 million

2) Consolidated Financial Position

Millions of yen

	As of March 31, 2009	As of March 31, 2008
Total assets.....	699,041	394,081
Net assets.....	543,070	256,758
Equity ratio (%).....	77.0%	64.5%
Net assets per share (¥).....	¥938.42	¥639.69

Note: Shareholders' equity: FY ended March 31, 2009: ¥538,554 million; FY ended March 31, 2008: ¥254,289 million

3) Consolidated Cash Flows

Millions of yen

	FY Ended March 31, 2009	FY Ended March 31, 2008
Net cash provided by operating activities.....	41,069	30,713
Net cash used in investing activities.....	(3,981)	(9,492)
Net cash used in financing activities.....	(20,978)	(13,499)
Cash and cash equivalents at end of period.....	69,286	44,118

2. Dividends

	FY Ended March 31, 2008	FY Ended March 31, 2009	FY Ending December 31, 2009 (forecast)
Dividend per share:			
Interim.....	¥5.00	¥10.00	¥10.00
Year-end.....	¥5.00	¥10.00	¥5.00
Annual.....	¥10.00	¥20.00	¥15.00
Total annual dividend amount (millions of yen).....	¥3,976	¥11,478	
Dividend payout ratio.....	16.9%	97.9%	66.2%
Ratio of dividends to net assets.....	1.6%	2.1%	

Note: Kyowa Hakko Kirin plans to change its fiscal year end from March 31 to December 31 and an extraordinary financial report will be prepared for the 9-month period resulting from the fiscal year end change. As a result of this change, the forecast dividend per share for the 9-month fiscal period ending December 31, 2009 will be ¥15 consisting of an interim dividend of ¥10 per share and a year-end dividend of ¥5 per share. This is based on the assumption of continued payment of a dividend of ¥20 per share for a 12-month period.

3. Consolidated Results Forecasts for the Fiscal Year Ending December 31, 2009

Millions of yen

	Interim		Full year	
		Change %		Change %
Net Sales	185,000	(25.3)	300,000	--
Operating income	14,500	(50.3)	27,000	--
Recurring income.....	15,000	(50.6)	27,500	--
Net income	6,500	(21.6)	13,000	--
Net income per share	¥11.33		¥22.65	

Notes: "Change %" indicates the percentage change compared to the previous interim period for interim forecasts.

Due to the change in financial year-end to December 31, the forecast figures for the full year are for the 9-month period from April 1, 2009 to December 31, 2009 and comparisons with the previous year are not provided.

4. Other

1) Transfer of important subsidiaries during the period (Transfers of certain subsidiaries resulting in changes in the scope of consolidation): Yes

Companies newly added: 2 (Kirin Pharma Company, Limited and Kyowa Hakko Bio Co., Ltd.)

Companies eliminated: 2 (Kirin Pharma Company, Limited and Kyowa Hakko Food Specialties Co., Ltd.)

Note: For details, see page 15, Section 2. Group Status.

2) Changes in accounting principles, procedures and presentation in the preparation of these financial statements

(1) Changes in accordance with revision to accounting standards: Yes

(2) Other changes: No

3) Number of shares outstanding (ordinary shares)

(1) Number of shares outstanding at end of period (including treasury shares):

March 31, 2009: 576,483,555 shares; March 31, 2008: 399,243,555 shares

(2) Number of treasury shares at end of period:

March 31, 2009: 2,589,766 shares; March 31, 2008: 1,723,184 shares

(Reference) 1. Non-Consolidated Financial Results for the Fiscal Year Ended March 31, 2009

1) Non-Consolidated Operating Results

Millions of yen; % changes are from the previous fiscal period

(Amounts less than 1 million yen have been ignored)

	FY Ended March 31, 2009		FY Ended March 31, 2008	
		Change (%)		Change (%)
Net sales	188,150	3.1	182,498	6.1
Operating income	35,916	46.6	24,505	34.3
Recurring income	40,427	54.9	26,093	10.3
Net income	34,059	107.2	16,438	(11.3)
Net income per share (¥)	¥59.33		41.33	
Fully diluted net income per share (¥)	¥59.30		41.30	

2) Non-Consolidated Financial Position

	As of March 31, 2009	As of March 31, 2008
Total assets (millions of yen)	365,522	283,153
Net assets (millions of yen)	285,676	206,649
Equity ratio (%)	78.1%	72.9%
Net assets per share (¥)	¥497.46	¥519.43

Note: Shareholders' equity: FY ended March 31, 2009: ¥285,487 million; FY ended March 31, 2008: ¥206,493 million

Notice regarding the appropriate use of the financial forecasts

- The above forecasts are based on the information available and assumptions made at the time of release of this document about a number of uncertain factors that may affect results in the future. Actual results can differ materially from these projections for a wide variety of reasons. For more information regarding our business forecasts, please refer to page 7, Operating results and financial position.
- On April 1, 2008, Kyowa Hakko Kirin, acting as the parent company of Kirin Pharma Company, Limited, implemented a share exchange making Kirin Pharma, a wholly owned subsidiary. Following this, as Kyowa Hakko Kirin became a subsidiary of Kirin Holdings, accounting regulations for business integration deem the share exchange a reverse acquisition, and the financial statements for the consolidated fiscal year ended March 31, 2009 have been prepared assuming that Kyowa Hakko has been acquired by Kirin Pharma. As a result, the balances at the end of the previous consolidated fiscal year in the consolidated financial statements for the previous fiscal year and the balances at the beginning of the current consolidated fiscal year in the consolidated financial statements for the current fiscal year differ, and therefore, comparisons with previous periods cannot be made.
- On October 1, 2008 Kyowa Hakko Kogyo Co., Ltd. merged with Kirin Pharma Company, Limited (Kyowa Hakko Kirin is the continuing company) and changed its name to Kyowa Hakko Kirin Co., Ltd.
- A proposal to change the fiscal year end from March 31 to December 31 has been submitted for approval at the General Meeting of Shareholders to be held on June 25, 2009.